3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
4
Neuroma, Acoustic
1
Neurofibromatosis 2
1
NSCLC
1
Meningioma
1
Lymphoma, Large-Cell, Anaplastic
1
Granuloma, Plasma Cell
1
Ependymoma
1
ALK-positive Advanced NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
Bevacizumab
2
neratinib
1
brigatinib
1
Sufentanil
1
Radiosurgery
1
Mn-PyC3A
1
Losartan
1
HDAC-42
1
Cochlear Implants
1
Aspirin
1
((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroma, Acoustic
×
brigatinib
×
1 year
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled